Publication
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Journal Paper/Review - Nov 26, 2021
Soo R A, Han J-Y, Dafni U, Cho B C, Yeo C M, Nadal E, Carcereny E, de Castro J, Sala M A, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S M S, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres J-M, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R A, Peters S, ETOP 10-16 BOOSTER Collaborators
Soo, R A
2
0
Han, J-Y
2
0
Dafni, U
2
0
Cho, B C
1
0
Yeo, C M
1
0
Nadal, E
2
0
Carcereny, E
2
0
de Castro, J
2
0
Sala, M A
2
0
Bernabé, R
2
0
Coate, L
2
0
Provencio Pulla, M
2
0
Garcia Campelo, R
1
0
Cuffe, S
2
0
Hashemi, S M S
2
0
Früh, M
6
0
Massuti, B
1
0
Garcia-Sanchez, J
1
0
Dómine, M
1
0
Majem, M
1
0